Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABBOTT LABORATORIESABT · Entity 2314 | Executive Vice President | February 28, 2017 | March 02, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABBOTT LABORATORIES
Report date February 28, 2017 · Filed March 02, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common shares without par valueSEC Table I · non-derivative | Direct | 69,240 |
Reported balance
After 2017-02-28 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2017-02-28 · Grant · Acquired 26,367 · Balance 69,240 F1: Settlement of a performance-based restricted stock unit in shares in a transaction exempt from Section 16(b) under Rule 16b-3. F2: Due to administrative error, the Form 4 previously filed on January 6, 2017 over-reported the shares acquired by 1 share. This Form 4 reflects the corrected total beneficial ownership for this reporting person. |
| Common shares without par valueSEC Table I · non-derivative | Direct | 60,359 |
Reported balance
After 2017-02-28 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2017-02-28 · Tax withholding · Disposed 8,881 · Balance 60,359 |
| Common shares without par valueSEC Table I · non-derivative | Direct | 56,508 |
Reported balance
After 2017-03-01 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2017-03-01 · Sale · Disposed 3,851 · Balance 56,508 |
| Common shares without par valueSEC Table I · non-derivative | IndirectBy Trust | 39,413 |
Reported balance
Holding disclosure · report date 2017-02-28 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 39,413 F3: Held in the Stefanie M. Warmuth Revocable Trust. The reporting person and his spouse are trustees of the trust. The trust is revocable by the reporting person's spouse. The reporting person disclaims beneficial ownership of these securities. |
Filing footnotes · ownership attribution and instrument terms
F1: Settlement of a performance-based restricted stock unit in shares in a transaction exempt from Section 16(b) under Rule 16b-3.
F2: Due to administrative error, the Form 4 previously filed on January 6, 2017 over-reported the shares acquired by 1 share. This Form 4 reflects the corrected total beneficial ownership for this reporting person.
F3: Held in the Stefanie M. Warmuth Revocable Trust. The reporting person and his spouse are trustees of the trust. The trust is revocable by the reporting person's spouse. The reporting person disclaims beneficial ownership of these securities.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 28, 2011 Filed Mar 2, 2011 22:13 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 6,054 | $47.64 | $288,412.56 |
DisclosureSEC source: 0001179110-11-003917 · edgar.xml · nonDerivative · entry 1 Warmuth Michael J · CIK 0001452290 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,866 F1 · balance_after: The number of shares beneficially owned by the reporting person has also been reduced by 270 shares to correct an inadvertent overstatement of the reporting person's beneficial ownership as reported on earlier forms. Read SEC document |
| February 18, 2011 Filed Feb 23, 2011 22:57 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 45,800 | $0.00 Strike: $46.60 | $0.00 |
DisclosureSEC source: 0001179110-11-003279 · edgar.xml · derivative · entry 1 Warmuth Michael J · CIK 0001452290 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,800 Underlying: Common shares · 45,800 shares Expires 2021-02-17 F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 15,267 on 02/18/2012, 15,266 on 02/18/2013, and 15,267 on 02/18/2014. Read SEC document |
| November 09, 2010 Filed Nov 10, 2010 22:02 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 11,172 | $0.00 Strike: $45.45 | $0.00 |
DisclosureSEC source: 0001179110-10-015828 · edgar.xml · derivative · entry 8 Warmuth Michael J · CIK 0001452290 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 11,172 shares Expires 2011-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| November 09, 2010 Filed Nov 10, 2010 22:02 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $50.10 | $5,010.03 |
DisclosureSEC source: 0001179110-10-015828 · edgar.xml · nonDerivative · entry 6 Warmuth Michael J · CIK 0001452290 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,190 Read SEC document |
| November 09, 2010 Filed Nov 10, 2010 22:02 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 6,300 | $50.10 | $315,636.30 |
DisclosureSEC source: 0001179110-10-015828 · edgar.xml · nonDerivative · entry 5 Warmuth Michael J · CIK 0001452290 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,290 Read SEC document |
| November 09, 2010 Filed Nov 10, 2010 22:02 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 200 | $50.10 | $10,020.30 |
DisclosureSEC source: 0001179110-10-015828 · edgar.xml · nonDerivative · entry 4 Warmuth Michael J · CIK 0001452290 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,590 Read SEC document |
| November 09, 2010 Filed Nov 10, 2010 22:02 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 200 | $50.10 | $10,020.14 |
DisclosureSEC source: 0001179110-10-015828 · edgar.xml · nonDerivative · entry 3 Warmuth Michael J · CIK 0001452290 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,790 Read SEC document |
| November 09, 2010 Filed Nov 10, 2010 22:02 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 4,372 | $50.10 | $219,037.20 |
DisclosureSEC source: 0001179110-10-015828 · edgar.xml · nonDerivative · entry 2 Warmuth Michael J · CIK 0001452290 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,990 Read SEC document |
| November 09, 2010 Filed Nov 10, 2010 22:02 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 11,172 | $45.45 | $507,753.99 |
DisclosureSEC source: 0001179110-10-015828 · edgar.xml · nonDerivative · entry 1 Warmuth Michael J · CIK 0001452290 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,362 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 03, 2010 Filed May 5, 2010 21:07 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-10-007954 · edgar.xml · nonDerivative · entry 1 Warmuth Michael J · CIK 0001452290 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,190 F1 · shares: The shares represent a retention award of restricted stock under the Abbott Laboratories 2009 Incentive Stock Program. The awards generally vest on the third anniversary of their grant date and include the right to have stock withheld for tax purposes. Read SEC document |
| April 27, 2010 Filed Apr 27, 2010 22:25 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 24 | $50.16 | $1,203.88 |
DisclosureSEC source: 0001179110-10-007464 · edgar.xml · nonDerivative · entry 8 Warmuth Michael J · CIK 0001452290 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Indirect · Profit Sharing Trust Disclosed balance after: 0 F1 · shares: Balance in the Abbott Laboratories Stock Retirement Trust as of April 27, 2010. Read SEC document |
| April 26, 2010 Filed Apr 27, 2010 22:25 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 496 | $51.21 | $25,400.66 |
DisclosureSEC source: 0001179110-10-007464 · edgar.xml · nonDerivative · entry 7 Warmuth Michael J · CIK 0001452290 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,190 Read SEC document |
| April 26, 2010 Filed Apr 27, 2010 22:25 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $51.21 | $5,121.02 |
DisclosureSEC source: 0001179110-10-007464 · edgar.xml · nonDerivative · entry 6 Warmuth Michael J · CIK 0001452290 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,686 Read SEC document |
| April 26, 2010 Filed Apr 27, 2010 22:25 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 200 | $51.21 | $10,242.00 |
DisclosureSEC source: 0001179110-10-007464 · edgar.xml · nonDerivative · entry 5 Warmuth Michael J · CIK 0001452290 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,786 Read SEC document |
| April 26, 2010 Filed Apr 27, 2010 22:25 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $51.20 | $5,120.14 |
DisclosureSEC source: 0001179110-10-007464 · edgar.xml · nonDerivative · entry 4 Warmuth Michael J · CIK 0001452290 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,986 Read SEC document |
| April 26, 2010 Filed Apr 27, 2010 22:25 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $51.20 | $5,120.02 |
DisclosureSEC source: 0001179110-10-007464 · edgar.xml · nonDerivative · entry 3 Warmuth Michael J · CIK 0001452290 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,086 Read SEC document |
| April 26, 2010 Filed Apr 27, 2010 22:25 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,030 | $51.20 | $52,736.00 |
DisclosureSEC source: 0001179110-10-007464 · edgar.xml · nonDerivative · entry 2 Warmuth Michael J · CIK 0001452290 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,186 Read SEC document |
| April 26, 2010 Filed Apr 27, 2010 22:25 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 7,974 | $51.19 | $408,189.06 |
DisclosureSEC source: 0001179110-10-007464 · edgar.xml · nonDerivative · entry 1 Warmuth Michael J · CIK 0001452290 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,216 Read SEC document |
| February 26, 2010 Filed Mar 2, 2010 23:48 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 5,287 | $54.12 | $286,132.44 |
DisclosureSEC source: 0001179110-10-004228 · edgar.xml · nonDerivative · entry 1 Warmuth Michael J · CIK 0001452290 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,190 Read SEC document |
| February 19, 2010 Filed Feb 24, 2010 01:44 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 33,500 | $0.00 Strike: $54.50 | $0.00 |
DisclosureSEC source: 0001179110-10-003580 · edgar.xml · derivative · entry 5 Warmuth Michael J · CIK 0001452290 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,500 Underlying: Common shares · 33,500 shares Expires 2020-02-18 F5 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 11,167 on 2/19/2011, 11,166 on 2/19/2012, and 11,167 on 2/19/2013. Read SEC document |
| February 19, 2010 Filed Feb 24, 2010 01:44 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 21,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-10-003580 · edgar.xml · nonDerivative · entry 2 Warmuth Michael J · CIK 0001452290 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,477 F2 · shares: These shares represent a retention award of restricted stock under the Abbott Laboratories 2009 Incentive Stock Program. The awards generally vest on the third anniversary of their grant date and include the right to have stock withheld for tax purposes. Read SEC document |
| February 19, 2010 Filed Feb 24, 2010 01:44 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 22,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-10-003580 · edgar.xml · nonDerivative · entry 1 Warmuth Michael J · CIK 0001452290 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,477 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 16, 2010 Filed Feb 18, 2010 23:07 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,000 | $54.60 | $54,602.00 |
DisclosureSEC source: 0001179110-10-003132 · edgar.xml · nonDerivative · entry 2 Warmuth Michael J · CIK 0001452290 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,577 Read SEC document |
| February 16, 2010 Filed Feb 18, 2010 23:07 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 2,996 | $53.93 | $161,574.28 |
DisclosureSEC source: 0001179110-10-003132 · edgar.xml · nonDerivative · entry 1 Warmuth Michael J · CIK 0001452290 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,577 Read SEC document |
| December 28, 2009 Filed Dec 29, 2009 23:06 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 1,849 | $0.00 Strike: $54.05 | $0.00 |
DisclosureSEC source: 0001179110-09-017534 · edgar.xml · derivative · entry 5 Warmuth Michael J · CIK 0001452290 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 1,849 shares Expires 2010-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| December 28, 2009 Filed Dec 29, 2009 23:06 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,849 | $54.50 | $100,770.50 |
DisclosureSEC source: 0001179110-09-017534 · edgar.xml · nonDerivative · entry 2 Warmuth Michael J · CIK 0001452290 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,573 Read SEC document |
| December 28, 2009 Filed Dec 29, 2009 23:06 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 1,849 | $54.05 | $99,938.45 |
DisclosureSEC source: 0001179110-09-017534 · edgar.xml · nonDerivative · entry 1 Warmuth Michael J · CIK 0001452290 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,422 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 20, 2009 Filed Oct 22, 2009 21:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 6,274 | $0.00 Strike: $52.23 | $0.00 |
DisclosureSEC source: 0001179110-09-014714 · edgar.xml · derivative · entry 6 Warmuth Michael J · CIK 0001452290 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,274 Underlying: Common shares · 6,274 shares Expires 2014-02-19 F4 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| October 20, 2009 Filed Oct 22, 2009 21:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 7,392 | $0.00 Strike: $41.03 | $0.00 |
DisclosureSEC source: 0001179110-09-014714 · edgar.xml · derivative · entry 5 Warmuth Michael J · CIK 0001452290 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 7,392 shares Expires 2014-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| October 20, 2009 Filed Oct 22, 2009 21:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 6,274 | $52.23 | $327,691.02 |
DisclosureSEC source: 0001179110-09-014714 · edgar.xml · nonDerivative · entry 2 Warmuth Michael J · CIK 0001452290 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,573 Read SEC document |
| October 20, 2009 Filed Oct 22, 2009 21:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 7,392 | $41.03 | $303,306.33 |
DisclosureSEC source: 0001179110-09-014714 · edgar.xml · nonDerivative · entry 1 Warmuth Michael J · CIK 0001452290 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,847 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 16, 2009 Filed Oct 20, 2009 22:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 3,572 | $0.00 Strike: $51.91 | $0.00 |
DisclosureSEC source: 0001179110-09-014651 · edgar.xml · derivative · entry 6 Warmuth Michael J · CIK 0001452290 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,572 Underlying: Common shares · 3,572 shares Expires 2014-02-19 F4 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| October 16, 2009 Filed Oct 20, 2009 22:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 4,192 | $0.00 Strike: $41.03 | $0.00 |
DisclosureSEC source: 0001179110-09-014651 · edgar.xml · derivative · entry 5 Warmuth Michael J · CIK 0001452290 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,392 Underlying: Common shares · 4,192 shares Expires 2014-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| October 16, 2009 Filed Oct 20, 2009 22:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 3,572 | $51.91 | $185,422.52 |
DisclosureSEC source: 0001179110-09-014651 · edgar.xml · nonDerivative · entry 2 Warmuth Michael J · CIK 0001452290 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,455 Read SEC document |
| October 16, 2009 Filed Oct 20, 2009 22:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 4,192 | $41.03 | $172,004.89 |
DisclosureSEC source: 0001179110-09-014651 · edgar.xml · nonDerivative · entry 1 Warmuth Michael J · CIK 0001452290 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,027 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 27, 2009 Filed Mar 4, 2009 00:26 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 434 | $48.76 | $21,162.71 |
DisclosureSEC source: 0001104659-09-013958 · a4.xml · nonDerivative · entry 2 Warmuth Michael J · CIK 0001452290 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,153 Read SEC document |
| February 27, 2009 Filed Mar 4, 2009 00:26 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 1,277 | $50.58 | $64,590.66 |
DisclosureSEC source: 0001104659-09-013958 · a4.xml · nonDerivative · entry 1 Warmuth Michael J · CIK 0001452290 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,587 Read SEC document |
| February 27, 2009 Filed Mar 27, 2009 21:26 UTC Amendment | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 434 | $48.76 | $21,162.71 |
DisclosureSEC source: 0001104659-09-020994 · a4a.xml · nonDerivative · entry 1 Warmuth Michael J · CIK 0001452290 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,835 F1 · balance_after: As reflected on the reporting person's Form 3/A and Form 4/A filed on March 27, 2009, the reporting person's Form 4 filed on February 27, 2009, understated the reporting person's beneficial ownership by 682 shares. Read SEC document |
| February 20, 2009 Filed Feb 24, 2009 22:01 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 38,700 | $0.00 Strike: $54.14 | $0.00 |
DisclosureSEC source: 0001104659-09-011803 · a4.xml · derivative · entry 4 Warmuth Michael J · CIK 0001452290 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,700 Underlying: Common shares · 38,700 shares Expires 2019-02-19 F4 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 12,900 on 02/20/2010, 12,900 on 02/20/2011, and 12,900 on 02/20/2012. Read SEC document |
| February 20, 2009 Filed Feb 24, 2009 22:01 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 27,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-09-011803 · a4.xml · nonDerivative · entry 1 Warmuth Michael J · CIK 0001452290 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,864 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 1996 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 17, 2009 Filed Feb 19, 2009 21:30 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 97 | $54.37 | $5,273.89 |
DisclosureSEC source: 0001104659-09-010781 · a4.xml · nonDerivative · entry 1 Warmuth Michael J · CIK 0001452290 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,664 Read SEC document |
| February 17, 2009 Filed Mar 27, 2009 21:24 UTC Amendment | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 285 | $54.94 | $15,657.90 |
DisclosureSEC source: 0001104659-09-020993 · a4a.xml · nonDerivative · entry 1 Warmuth Michael J · CIK 0001452290 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,346 F1 · shares: The reporting person's Form 4 filed on February 19, 2009, did not report the withholding of 285 shares to satisfy the reporting person's tax obligation in connection with the vesting of restricted stock units. Read SEC document |
| January 27, 2009 Filed Jan 30, 2009 01:01 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 3,368 | $0.00 Strike: $54.05 | $0.00 |
DisclosureSEC source: 0001104659-09-005106 · a4.xml · derivative · entry 18 Warmuth Michael J · CIK 0001452290 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,368 Underlying: Common shares · 3,368 shares Expires 2014-02-19 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| January 27, 2009 Filed Jan 30, 2009 01:01 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 6,146 | $0.00 Strike: $54.05 | $0.00 |
DisclosureSEC source: 0001104659-09-005106 · a4.xml · derivative · entry 17 Warmuth Michael J · CIK 0001452290 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,146 Underlying: Common shares · 6,146 shares Expires 2013-02-13 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| January 27, 2009 Filed Jan 30, 2009 01:01 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 1,849 | $0.00 Strike: $54.05 | $0.00 |
DisclosureSEC source: 0001104659-09-005106 · a4.xml · derivative · entry 16 Warmuth Michael J · CIK 0001452290 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,849 Underlying: Common shares · 1,849 shares Expires 2010-02-10 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| January 27, 2009 Filed Jan 30, 2009 01:01 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 1,815 | $0.00 Strike: $41.03 | $0.00 |
DisclosureSEC source: 0001104659-09-005106 · a4.xml · derivative · entry 15 Warmuth Michael J · CIK 0001452290 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,584 Underlying: Common shares · 1,815 shares Expires 2014-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| January 27, 2009 Filed Jan 30, 2009 01:01 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 2,454 | $0.00 Strike: $41.03 | $0.00 |
DisclosureSEC source: 0001104659-09-005106 · a4.xml · derivative · entry 14 Warmuth Michael J · CIK 0001452290 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 2,454 shares Expires 2014-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| January 27, 2009 Filed Jan 30, 2009 01:01 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 8,811 | $0.00 Strike: $33.23 | $0.00 |
DisclosureSEC source: 0001104659-09-005106 · a4.xml · derivative · entry 13 Warmuth Michael J · CIK 0001452290 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 8,811 shares Expires 2013-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| January 27, 2009 Filed Jan 30, 2009 01:01 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 3,065 | $0.00 Strike: $32.61 | $0.00 |
DisclosureSEC source: 0001104659-09-005106 · a4.xml · derivative · entry 12 Warmuth Michael J · CIK 0001452290 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 3,065 shares Expires 2010-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| January 27, 2009 Filed Jan 30, 2009 01:01 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 4,514 | $0.00 Strike: $54.03 | $0.00 |
DisclosureSEC source: 0001104659-09-005106 · a4.xml · derivative · entry 11 Warmuth Michael J · CIK 0001452290 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 4,514 shares Expires 2009-02-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.